News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We need a mfing update and we'll get to .20s
Only took a couple of days
Sounds like we will have several PRs describing in detail each one of these entities.
We'll break into the .20s very soon
04/15/2025 Pink Open Market Logo KRTL KRTL Holding Group, Inc Pink Limited Pink Current
Andre 3000
@goinggreen777
·
1m
$KRTL, Last trade .1533. Company news drop expected shortly. Market conditions have improved leading to the anticipated rocket ride to the 1.50 level to begin just in time for the Sigma Corp. merger news to act as the intrinsic catalyst. Strong buy
@GoingGreenPicks
@PEM77
imo. $T
KRTL one of the best set-ups out there with zero toxic = zero dilution mergers coming in
KRTL .1533s up lets go bring on .20s
KRTL .14s blown out today, zero dilution zero toxic moves so easily with just a little buying volume
$KRTL Tech Spotlight:
Neurogen’s non-invasive neuromodulation therapy enhances cognitive performance, stress reduction, and trauma recovery—offering scalable, drug-free mental wellness solutions. https://www.otcmarkets.com/stock/KRTL/news/KRTL-Holding-Announces-Acquisition-of-Neurogen-Brain-Balancing-LLC--A-Strategic-Merger-Accelerating-Global-Neurotech-and?id=473095 https://neurogenbb.com/
Xstocklpicker88
@xstocklpicker88
·
1h
$KRTL has been making strategic moves to expand its presence in the biopharmaceutical sector, particularly through partnerships in Bolivia. For instance, KRTL Biotech Inc., a subsidiary of KRTL Holding Group, has formed a joint venture with Centro de Investigaciones Químicas (CIQ) in Bolivia to leverage the country’s natural resources for API production. This collaboration aims to introduce Bolivian-sourced APIs, raw materials, and other compounds into the U.S. market, following regulatory approval. Bolivia’s cost-effective production and rich biodiversity are seen as advantages that could diversify the global supply chain, which has long been dominated by countries like China and India.
Additionally, KRTL has been involved in merger-related activities. Just yesterday, on April 9, 2025, KRTL Holding announced the acquisition of Neurogen Brain Balancing, LLC, a California-based neurotechnology company. This merger is intended to bolster KRTL’s position in the mental wellness and neuroscience sectors, though it doesn’t directly tie to the Bolivia API supply chain. However, earlier in 2025, KRTL Biotech signed a Memorandum of Understanding (MOU) with Industria Químico Farmacéutica Sigma Corp. S.R.L. in Bolivia, outlining a framework for a strategic international merger. This deal focuses on integrating Sigma’s manufacturing operations and revenue streams into KRTL Biotech, with plans to import and commercialize Sigma’s pharmaceutical products in the U.S. This could be the merger news you’re anticipating, especially as it aligns with the API supply chain narrative.
The Bolivia-to-U.S. supply chain initiative is positioned as a way to enhance operational efficiency and reduce reliance on traditional pharmaceutical hubs. For example, Sigma’s production facilities in Bolivia, currently operating at about 40% capacity, could scale up significantly through this partnership, potentially offering a competitive alternative to China’s API market. Posts on X also reflect optimism about KRTL’s stock, suggesting that upcoming news—possibly merger-related—could drive significant interest, with some users framing it as a “Make America Healthy Again” (#MAHA) play due to its potential to lower drug costs in the U.S.
If you’re expecting specific merger news beyond what’s already been announced, it could relate to further developments in the KRTL-Sigma partnership or additional acquisitions. The final Business Merger Agreement with Sigma is still under development, pending legal and financial conditions, so an update on that front might be imminent. Given the current date of April 10, 2025, and the announcement of the Neurogen acquisition just a day ago, KRTL appears to be in an active phase of expansion, which could mean more news is on the horizon.
$KRTL KRTL Holding Announces Acquisition of Neurogen Brain Balancing, LLC – A Strategic Merger Accelerating Global Neurotech and Mental Wellness Expansion
https://www.globenewswire.com/news-release/2025/04/09/3058458/0/en/KRTL-Holding-Announces-Acquisition-of-Neurogen-Brain-Balancing-LLC-A-Strategic-Merger-Accelerating-Global-Neurotech-and-Mental-Wellness-Expansion.html
KRTL Holding Announces Acquisition of Neurogen Brain Balancing, LLC – A Strategic Merger Accelerating Global Neurotech and Mental Wellness Expansion
KRTL Holding Group Inc., a diversified international enterprise focused on biotech innovation, regulatory infrastructure, and strategic investment, is pleased to announce the acquisition of Neurogen Brain Balancing, LLC, a California-based neurotechnology company known for its advanced brain balancing therapies and personalized cognitive optimization systems. This transformative acquisition expands KRTL’s presence in the mental wellness space and enhances its position at the intersection of neuroscience, biotechnology, and global healthcare.
This acquisition establishes Neurogen as a subsidiary of KRTL Holding Group Inc., representing a pivotal step in the company’s broader strategy to integrate advanced neurotechnology into its ecosystem and support the growth of scalable mental health solutions.
Under the terms of the transaction, KRTL has acquired 100% of Neurogen’s equity through a stock-based structure that also includes a collaborative profit-sharing agreement. Additional elements of the consideration include KRTL’s commitment to support Neurogen’s entry into new markets and provide FDA-related services to enhance regulatory pathways and strategic growth alignment between the two companies.
“We are thrilled to welcome Neurogen into the KRTL Holding Group family,” said Cesar Herrera, CEO of KRTL Holding Group. “In today’s rapidly evolving global environment, diversification is not just a strategy—it’s a necessity. By bringing Neurogen into our ecosystem, we strengthen our ability to remain agile, resilient, and forward-thinking across multiple sectors. Their innovative work is a natural fit for our mission to invest in businesses that shape the future.”
Neurogen’s proprietary neurotechnology utilizes advanced neuromodulation protocols that support applications ranging from cognitive performance enhancement to stress reduction and post-trauma recovery. The platform is particularly well-positioned to address critical gaps in the continuation of care for patients seeking alternative therapies. By offering non-opioid, non-invasive treatment options with simplified access, the technology aligns with broader healthcare priorities around expanding safe, effective, and accessible behavioral and neurological health interventions.
"This acquisition marks an exciting new chapter for Neurogen. Joining forces with KRTL Holding Group enables us to accelerate our mission of transforming mental health treatment through cutting-edge neurotechnology. With KRTL’s global infrastructure and regulatory expertise, we’re well-positioned to scale our solutions and reach underserved communities worldwide. Together, we aim to expand access to non-invasive, personalized brain health therapies—advancing a new global standard for neurological wellness," said Gregory Gillispie, President of NeuroGen. "The guidance and infrastructure offered by KRTL enhance our ability to grow responsibly while continuing to focus on improving lives through brain balance."
Strategic Integration and Global Expansion Framework
As part of the integration, Neurogen is being incorporated into KRTL’s operational and regulatory infrastructure. These efforts, which include brand alignment across digital channels and investor communications, financial system harmonization, and scalable operational planning, are underway and being informed by both internal leadership and third-party advisors.
KRTL’s internal systems, including its Quality Management System (QMS) and Enterprise Resource Planning (ERP) infrastructure, are currently under expert review. This assessment is aimed at identifying the most effective enhancements to support joint business capabilities and long-term performance.
Further coordination is focused on regulatory and clinical alignment, including FDA-compliant trial design and support for international submissions. Neurogen is also positioned to participate in real-world data research through its connection with Centro de Investigaciones Químicas - CIQ S.R.L in Bolivia, contributing to global product validation efforts.
As the collaboration evolves, KRTL intends to issue follow-up announcements that will provide added clarity, updates on integration progress, and forward-looking insights.
KRTL Holding Announces Acquisition of Neurogen Brain Balancing, LLC – A Strategic Merger Accelerating Global Neurotech and Mental Wellness Expansion
Press Release | 04/09/2025
Lakewood, CO, April 09, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE
KRTL Holding Announces Acquisition of Neurogen Brain Balancing, LLC – A Strategic Merger Accelerating Global Neurotech and Mental Wellness Expansion
KRTL Holding Group Inc., a diversified international enterprise focused on biotech innovation, regulatory infrastructure, and strategic investment, is pleased to announce the acquisition of Neurogen Brain Balancing, LLC, a California-based neurotechnology company known for its advanced brain balancing therapies and personalized cognitive optimization systems. This transformative acquisition expands KRTL’s presence in the mental wellness space and enhances its position at the intersection of neuroscience, biotechnology, and global healthcare.
This acquisition establishes Neurogen as a subsidiary of KRTL Holding Group Inc., representing a pivotal step in the company’s broader strategy to integrate advanced neurotechnology into its ecosystem and support the growth of scalable mental health solutions.
Under the terms of the transaction, KRTL has acquired 100% of Neurogen’s equity through a stock-based structure that also includes a collaborative profit-sharing agreement. Additional elements of the consideration include KRTL’s commitment to support Neurogen’s entry into new markets and provide FDA-related services to enhance regulatory pathways and strategic growth alignment between the two companies.
“We are thrilled to welcome Neurogen into the KRTL Holding Group family,” said Cesar Herrera, CEO of KRTL Holding Group. “In today’s rapidly evolving global environment, diversification is not just a strategy—it’s a necessity. By bringing Neurogen into our ecosystem, we strengthen our ability to remain agile, resilient, and forward-thinking across multiple sectors. Their innovative work is a natural fit for our mission to invest in businesses that shape the future.”
Neurogen’s proprietary neurotechnology utilizes advanced neuromodulation protocols that support applications ranging from cognitive performance enhancement to stress reduction and post-trauma recovery. The platform is particularly well-positioned to address critical gaps in the continuation of care for patients seeking alternative therapies. By offering non-opioid, non-invasive treatment options with simplified access, the technology aligns with broader healthcare priorities around expanding safe, effective, and accessible behavioral and neurological health interventions.
"This acquisition marks an exciting new chapter for Neurogen. Joining forces with KRTL Holding Group enables us to accelerate our mission of transforming mental health treatment through cutting-edge neurotechnology. With KRTL’s global infrastructure and regulatory expertise, we’re well-positioned to scale our solutions and reach underserved communities worldwide. Together, we aim to expand access to non-invasive, personalized brain health therapies—advancing a new global standard for neurological wellness," said Gregory Gillispie, President of NeuroGen. "The guidance and infrastructure offered by KRTL enhance our ability to grow responsibly while continuing to focus on improving lives through brain balance."
Strategic Integration and Global Expansion Framework
As part of the integration, Neurogen is being incorporated into KRTL’s operational and regulatory infrastructure. These efforts, which include brand alignment across digital channels and investor communications, financial system harmonization, and scalable operational planning, are underway and being informed by both internal leadership and third-party advisors.
KRTL’s internal systems, including its Quality Management System (QMS) and Enterprise Resource Planning (ERP) infrastructure, are currently under expert review. This assessment is aimed at identifying the most effective enhancements to support joint business capabilities and long-term performance.
Further coordination is focused on regulatory and clinical alignment, including FDA-compliant trial design and support for international submissions. Neurogen is also positioned to participate in real-world data research through its connection with Centro de Investigaciones Químicas - CIQ S.R.L in Bolivia, contributing to global product validation efforts.
As the collaboration evolves, KRTL intends to issue follow-up announcements that will provide added clarity, updates on integration progress, and forward-looking insights.
About KRTL Holding Group Inc.
KRTL Holding Group Inc. is a dynamic holding company operating through its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. These subsidiaries specialize in biopharmaceutical innovation, international trade, and compliance-driven healthcare advancements. By leveraging strategic mergers, acquisitions, and joint ventures, KRTL Holding Group continues to push the boundaries of scientific research, regulatory compliance, and global business solutions.
Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, anticipated business developments, regulatory advancements, and strategic growth plans. Such forward-looking statements involve known and unknown risks that may cause actual results to differ materially from those expressed or implied.
KRTL Holding Group assumes no obligation to update or revise forward-looking statements, except as required by law. Any updates will be made in accordance with applicable SEC regulations and disclosure obligations. Readers are cautioned not to place undue reliance on forward-looking statements.
www.krtlholding.com
info@krtlholding.com
www.krtlbiotech.com
info@krtlbiotech.com
www.krtl-icc.com
info@krtl-icc.com
Thanks. Looking forward to it and much more. Awesome close here today at .149
This is string and when it's above 2.15 it's at 4.50 as a buy we going to MOVE WAYYYYY UP
BUY IT BARCHART SAYS SOO!!! 🚀🚀🚀🚀🚀
KRTLBIOTECH OTC:KRTL
@KRTLBiotech
·
2h
Attention $KRTL shareholders:
A press release is scheduled for tomorrow — with more updates to follow. Stay tuned.
This ticker has held up amazingly and we still have alot of amazing developments ahead
KRTL .149s some nice slaps this is ready for new highs anytime here
Xstocklpicker88
@xstocklpicker88
·
35m
KRTL Biotech, Inc. (referred to as KRTL in posts on X and various web sources) appears to be taking steps to enter the pharmaceutical Active Pharmaceutical Ingredient (API) market in the USA, though detailed, official documentation directly from the company is limited in the provided references. Based on available information, including posts on X and broader context about the U.S. API market, here’s how KRTL seems to be approaching this venture as of April 3, 2025.
KRTL is focusing on regulatory compliance as a foundational step. Posts on X from early April 2025 indicate that the company has strengthened its FDA registration and implemented a Quality Management System (QMS) aligned with international standards. This suggests that KRTL is prioritizing adherence to the stringent regulatory requirements set by the U.S. Food and Drug Administration (FDA), which is a critical prerequisite for any company entering the U.S. pharmaceutical API market. Compliance with FDA standards ensures that their APIs meet safety, efficacy, and quality benchmarks, a necessity given that the U.S. market demands high-quality production, especially for domestic consumption.
Additionally, KRTL’s strategy seems to involve securing FDA-compliant supply chains, as highlighted in an X post on April 2, 2025. This focus on supply chain integrity aligns with broader trends in the U.S. API market, where there’s increasing emphasis on reducing reliance on foreign suppliers (e.g., China and India) and bolstering domestic production. The U.S. produces a significant portion of APIs by dollar value (around 53-54% in recent years according to Avalere’s analyses), but only about 28% of API manufacturing facilities are U.S.-based, per FDA data. KRTL’s efforts to establish compliant supply chains could position it to capitalize on this push for localized manufacturing, potentially targeting partnerships or contracts with U.S.-based pharmaceutical companies seeking reliable domestic API sources.
While specific details about KRTL’s product pipeline or exact entry tactics (e.g., whether they’re focusing on generic APIs, innovative APIs, or high-potency APIs like those used in oncology) aren’t explicitly outlined in the available data, their emphasis on innovation—mentioned in the same X post—suggests they may be exploring niche or high-value API segments. The U.S. API market is projected to grow significantly, with estimates ranging from $72.21 billion by 2033 (BioSpace) to higher figures globally, driven by demand for chronic disease treatments and biologics. KRTL’s mission to “drive innovation” could imply investment in research and development to produce specialized APIs, possibly leveraging advanced manufacturing technologies, which the FDA has identified as a way for U.S.-based companies to compete with lower-cost foreign producers.
Operationally, KRTL is likely establishing or expanding manufacturing capabilities to meet these goals. While the references don’t confirm specific facility locations or partnerships, the company’s FDA registration efforts and QMS implementation suggest they are either building new facilities or retrofitting existing ones to comply with Good Manufacturing Practices (GMP). This aligns with industry trends where companies like Cambrex and Millipore Sigma have recently expanded U.S.-based API production capacity (e.g., Cambrex’s $38 million facility in 2023 and Millipore Sigma’s $69 million HPAPI expansion in 2023).
In summary, KRTL is entering the U.S. pharmaceutical API market by focusing on FDA compliance, establishing a robust QMS, and securing compliant supply chains, with an apparent aim to innovate within the sector. This approach positions them to meet the growing demand for domestically produced APIs, though their success will depend on execution details like product focus, manufacturing scale, and market partnerships—areas where more concrete information would provide further clarity.
Startup King
@PEM77777777
·
5h
$The $KRTL merger aims to integrate Sigma’s manufacturing operations and $20 million revenue stream into KRTL Biotech, with projections of 100% growth and plans for U.S. market expansion. The news has generated buzz, with some speculation that the stock price runs to 1.50 imo. T-Money-Millionaire
@tmoney777777777
·
5h
Loading $KRTL at .12. News will drop any second according to company management. If we get #merger #press 1.00 plus in 2 sessions imo.
PikachOTC
@PikachOTC
·
16m
If you're selling your #OTC because of big boards panic, you are doing a big mistake.
This exchange will trade on its own no matter the conditions. Good or bad.
I estimate at least $41M from the first two big ones combined and yes this recent Neurogen Brain Balance acquisition is separate from those.
If both mergers have a combined revenue of 38 mil and you divide that by the issued common stock of 87 mil that would give us a share price of .43. And that's with out using any EBITA multipliers, which ALL companies do have a multiplier. A 10x multiplier would give us a share price of 4.3, which I believe is more realistic.
Less, but not much less. The most I can say about that. Exciting stuff coming 🔥
Holy cow! Did we just have a GREEN Friday Been a few weeks haven't in a Row YESSSSS!!!! Gone get my free grill set and $75 free comp play at the casino! Made bank off of ICCT and AREB today wow what a ride!!!!!! 🚀🚀🚀🚀🚀
KRTL nice ask slapping into close here, should see a huge run once more details of merger released, tiny floater
KRTL has one of the best set-ups in all OTCs
Soooo does the second merger have more or less revenue than Sigma?:)
Quite a while for a company like SIGMA. I won't get into all the things involved, but there is a lot that has been done and approved. The good news is it's already far into being completely finalized, so just hold on 😉
Another merger is far into being done as well. Good times coming 💰️
|
Followers
|
97
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
10025
|
|
Created
|
05/06/20
|
Type
|
Free
|
| Moderators ProfitChaser threewheeler TimeIsFading | |||
Main Website - https://www.krtlholding.com
KRTL International - https://www.krtl-icc.com
| PUBLISH DATE | TITLE | PERIOD END DATE | STATUS |
|---|---|---|---|
| 08/13/2023 | Quarterly Report - Disclosure Report and Consolidated Financial Statements | 06/30/2023 | A |
| 05/15/2023 | Quarterly Report - Disclosure Report and Consolidated Financial Statements | 03/31/2023 | A |
| 04/03/2023 | Attorney Letter with Respect to Current Information - 12/31/2022 Attorney Letter | 12/31/2022 | A |
| 03/23/2023 | Annual Report - Disclosure Report and Financial Statements (Amended) | 12/31/2022 | A |
| 03/15/2023 | Annual Report - Disclosure Statement with Consolidated Financial Statements | 12/31/2022 | A |
| 01/09/2023 | Supplemental Information - Change in Shell Status | 06/30/2022 | A |
| 11/12/2022 | Quarterly Report - Disclosure Report and Financial Statements | 09/30/2022 | A |
| 07/31/2022 | Quarterly Report - Disclosure Report and Financial Statements | 06/30/2022 | A |
| 05/18/2022 | Quarterly Report - Disclosure Report and Financial Statement | 03/31/2022 | A |
| 03/29/2022 | Attorney Letter with Respect to Current Information - Period 12/31/21 | 12/31/2021 | A |
AI
